Compare Constellation Energy Corporation (CEG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Constellation Energy Corporation vs Neurocrine Biosciences Inc — how do they compare? Constellation Energy Corporation trades at $279.76 (market cap $95.82B), while Neurocrine Biosciences Inc trades at $157.49 (market cap $16.76B). The key difference: Constellation Energy Corporation is far larger — about 5.7× Neurocrine Biosciences Inc's market cap, and Constellation Energy Corporation pays a 0.63% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| CEG | NBIX | |
|---|---|---|
Market Cap | $95.82B | $16.76B |
Sector | Energy | Health |
52-Week High | $403.95 | $185.50 |
52-Week Low | $236.50 | $123.10 |
Enterprise Value | $119.82B | $16.78B |
Dividend Yield | 0.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Constellation Energy (CEG) trades at $269.89, up 3.37% with a bullish technical outlook. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $2.55 versus $2.29 expected, and the company raised its 2026 guidance. Recent news highlights new power deals, including a Walmart PPA, and the acquisition of Calpine, positioning CEG to benefit from AI-driven electricity demand.
The outlook is positive with a consensus price target of $333.14, implying significant upside. Key opportunities include nuclear energy's role in the AI power boom and strong cash flow generation. Risks involve execution of growth initiatives and potential regulatory changes affecting the utilities sector.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
